CYP3A4 and torsades de pointes: Exkivity may lead to QTc prolongation and/or torsades de pointes. If this happens, reduce the dose or discontinue Exkivity based on the severity of QTc prolongation. Discontinue Exkivity if the patient shows induction of interstitial lung disease/pneumonitis, cardiac toxicity, diarrhea, and embryo-fetal toxicity. Additionally, avoid concomitant use of CYP3A inhibitors with Exkivity that can prolong QTc [29,30]